Huntington’s disease is a progressive degeneration of the neurons in the brain resulting in loss of cognition, motor ability, uncontrolled movements and emotional distress. The disease can be categorized into adult onset, which manifests in the form of depression, irritability, lack of coordination and poor...
GreenLane Holdings Inc (NASDAQ: GNLN), a Company dealing in wholesale and retail distribution of consumption accessories and vaporization products, announced a comprehensive distribution agreement with Advanced Vapor Devices (AVD), a manufacturer of vaporizer cartridges and batteries. The agreement will cover the entire range of AVD...
ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older...
Telenav Inc (NASDAQ: TNAV), a pioneer in the Automotive and Mobile Navigation segments, announced that it will extend its collaboration with Amazon to offer voice-first navigation through Alexa, providing drivers with a hands-free, intelligent navigation option, even in cases of poor or non-existent mobile reception....
Wave Life Sciences (NASDAQ: WVE), a clinical-stage Company developing novel stereopure oligonucleotides to treat genetic defects, announced topline data from an ongoing Phase 1b/2a PRECISION-HD2 trial evaluating the safety and efficacy of WVE-120102, a first-in-class allele-selective approach to treat Huntington’s disease (HD). The study shows...
Pulmatrix Inc (NASDAQ: PULM), a Clinical Stage Biopharmaceutical Company developing inhaled therapies for the treatment of pulmonary diseases, announced the signing of a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (NYSE: JNJ), enabling the initiative to access the Company’s...
Savara Inc (NASDAQ: SVRA), a Company focused on addressing the needs of orphan lung diseases, announced the grant of a breakthrough designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), indicated for the treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). The US...
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a Company focussed on developing autologous cellular therapies for neurodegenerative diseases, has been awarded the Buzz of Bio 2020 in the public therapeutic biotech category. The award recognises the efforts of Brainstorm in the field of neurodegenerative diseases, including progressive...
Education Technology is a burgeoning industry owing to a rise in internet penetration and use of smart phones. There is a growing acceptance of e-learning and many governments are providing impetus to e-learning initiatives. The advancements witnessed in the smart phone technology have revolutionized the...
Avenue Therapeutics (NASDAQ: ATXI), a subsidiary of Fortress Biotech Inc, announced the submission of a New Drug Application (NDA) to the FDA, for IV tramadol, an intravenous solution intended for the treatment of moderate to moderately severe pain in adults. The Company is focused on...
